DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities (Q40671125)

22 September 2017

DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities (English)

1 reference

22 September 2017

Reeba K Vikramadithyan

1

1 reference

22 September 2017

Jagadheshan Hiriyan

2

1 reference

22 September 2017

Juluri Suresh

3

1 reference

22 September 2017

Cynthia Gershome

4

1 reference

22 September 2017

Ravi K Babu

5

1 reference

22 September 2017

Parimal Misra

6

1 reference

22 September 2017

Ramanujam Rajagopalan

7

1 reference

22 September 2017

Ranjan Chakrabarti

8

1 reference

22 September 2017

1 February 2003

1 reference

22 September 2017

1 reference

22 September 2017

11

1 reference

22 September 2017

2

1 reference

22 September 2017

292-303

1 reference

Banting lecture 1988. Role of insulin resistance in human disease

22 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Roles of PPARs in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical mode

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Bromocriptine/SKF38393 treatment ameliorates dyslipidemia in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

The hormonal and metabolic basis of experimental obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Insulin resistance in genetically obese, hyperglycemic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Bezafibrate reduces blood glucose in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Cholesterol lowering action of HOE 402 in the normolipidemic and hypercholesterolemic golden Syrian hamster

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Obesity as a medical problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Purification and characterization of the isozymes of phosphoenolpyruvate carboxykinase from rabbit liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

A rapid spectrophotometric assay for carnitine palmitoyltransferase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

42 Peroxisomal and microsomal carnitine acetyltransferases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Purification of clofibrate-induced carnitine acetyltransferase from rat liver mitochondria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Preparation, characterization, and measurement of lipoprotein lipase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.44

31 March 2020

Identifiers

DOI

10.1038/OBY.2003.44

1 reference

22 September 2017

1 reference